Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CBL-B inhibitor-treated autologous tumor-infiltrating lymphocytes DeTIL-0255

A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from a patient's tumor that have been treated ex vivo during cell expansion with NX-0255, an inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulating and antineoplastic activities. Upon administration, the CBL-B inhibitor-treated autologous TILs DeTIL-0255 specifically recognize and kill the patient's tumor cells. NX-0255 enhances TIL expansion and the tumor-killing ability of the TILs when returned to the patient.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologus TILs DeTIL-0255
DeTIL NX-0255
DeTIL NX-0255
DeTIL NX0255
NX-0255 drug-enhanced TILs
NX-0255-treated autologous TILs DeTIL-0255
Code name:DeTIL-0255
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search